Arlington Capital Partners (Arlington), a Washington, DC-based private investment firm specialising in government-regulated industries, has closed its fund Arlington Capital Partners VII, with capital commitments totalling $6bn. The fund was oversubscribed, reaching its hard cap in less than five months and surpassing its $4.75bn target. This represents a 57% increase over Arlington’s previous fund, which closed in 2023, and a more than 250% increase from its fifth fund, which closed in 2019.
Since its founding in 1999, Arlington has completed approximately 200 investments in its focus areas of aerospace and defence, government services and technology, and healthcare. The firm has invested over $1bn across 35 investments since the beginning of 2024, with exits such as the sale of BlueHalo to AV.
As the fund is deployed, the firm plans to focus on its long-term investment themes, including manufacturing and supply chain onshoring, improving government efficiency, defence tech, cybersecurity, commercial aviation, advanced medical device and life sciences development, and healthcare technology.
Evercore acted as Arlington’s exclusive global placement agent, and Simpson Thacher & Bartlett LLP served as fund counsel.
